HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.
Cheng, X.; Hsia, J.; Iraheta, J.; Gongora, J.; Highkin, M.; Jin, X.; Guo, Z.; Prior, J. L.; Edwards, J. R.; Li, S.; Hagemann, I. S.; Ma, C. X.; Lin, Z.; Garcia, B. A.; Bose, R.
Show abstract
In metastatic breast cancer, HER2-activating mutations often co-occur with TP53 mutations, a combination linked to poor response to neratinib and worse prognosis. To model this clinical challenge, we bred HER2 V777L transgenic mice with two TP53 mutant alleles: TP53 R172H (the murine homolog of human TP53 R175H) and TP53fl/fl, which mimics p53 truncations common in human tumors. TP53 mutations accelerated tumor development and reduced survival in HER2-mutant mice. These co-mutant tumors were resistant to neratinib but remained sensitive to exatecan, the topoisomerase I (TOP1) inhibitor payload in trastuzumab deruxtecan (T-DXd). Mechanistically, TP53 mutant tumors exhibited upregulation of histone acetylation, hypertranscription of DNA repair factors, increased chromatin accessibility, and rendered cells more susceptible to TOP1 inhibitors via G2/M arrest and apoptosis. This vulnerability is dependent on transcriptional activity of TP53 mutations, highlighting a novel strategy to treat HER2;TP53 co-mutant breast cancers using TOP1-targeted therapies. Statement of SignificanceTP53 mutations sensitize HER2-mutant cancers to TOP1 inhibitors via chromatin accessibility and hyper-transcription, supporting combination therapy with neratinib and T-DXd in TP53/HER2 co-mutant breast cancers.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer 96%
- Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer 95%
- A SNAI2-PEAK1 stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting a cytokine expression profile that converges on PI3K/Akt signaling 95%
Similar papers in this journal
- Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identifies essential kinases and synergy of EGFR and FGFR1 inhibition. 95%
- CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis 95%
- Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance 94%
Similar papers in this journal
- Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer 96%
- GLUT1 inhibition blocks growth of RB1-positive Triple Negative Breast Cancer 96%
- Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma 95%
Similar papers in this journal
- Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors 96%
- Ivermectin converts cold tumors hot and synergies with immune checkpoint blockade for treatment of breast cancer 94%
- The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer 94%
Similar papers in this journal
- BET inhibition induces an anti-apoptotic adaptive response and therapeutic vulnerability to MCL1 inhibitors in breast cancer 96%
- Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex 95%
- G9a Promotes Breast Cancer Recurrence Through Repression of a Pro-inflammatory Program 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.